A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma
- 24 January 2013
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 79 (3) , 409-415
Abstract
Summary: Context: Intensive treatment with cabergoline may lead to earlier reduction in prolactin and tumour volume in comparison to conventional schedule.Objective: To compare the efficacy and safety of two different dosing schedules of cabergoline in patients with macroprolactinoma.Design: Prospective, randomized trial in drug naive patients assigned to conventional (4 weekly escalation by 0·5 mg per week, group A) or intensive (weekly increase by 1 mg per week followed by 4 weekly escalation, group B) treatment with cabergoline.Outcome measure: The duration required to achieve normoprolactinemia and tumour shrinkage of >50% as a composite end‐point.Results: 38 patients (19 in each group) completed the study with a mean follow‐up of 64·3 ± 24·9 weeks. More subjects (22%) achieved the composite end‐point in group B (18/19) as compared to the group A (14/19) (P = 0·18). The duration of cabergoline treatment required to achieve the composite end‐point was 13·1 ± 9·5 weeks vs 19·3 ± 15·7 weeks (P = 0·34) in the group A and B, respectively. A reduction in prolactin of ≥90% by the fourth week of cabergoline therapy predicted subsequent normalization of prolactin (AUC 0·78; P = 0·04). A further increase in cabergoline dosage after normalization of prolactin in patients with tumour reduction of <50%, led to further tumour shrinkage by 31·2% in an additional 26·3% of patients.Conclusions: Intensive treatment with cabergoline is not superior to the conventional recommended dosage schedule in respect to the time necessary to achieve normoprolactinemia and ≥50% tumour shrinkage. Clinical trial registry: NCT 01143584.Keywords
This publication has 22 references indexed in Scilit:
- Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomasPituitary, 2008
- Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemiaInternational Journal Of Clinical Practice, 2008
- Guidelines of the Pituitary Society for the diagnosis and management of prolactinomasClinical Endocrinology, 2006
- Pharmacologic Resistance in Prolactinoma PatientsPituitary, 2005
- ProlactinomaNew England Journal of Medicine, 2003
- Clinical Pharmacokinetics of CabergolineClinical Pharmacokinetics, 2003
- Dopamine receptor agonists for treating prolactinomasExpert Opinion on Investigational Drugs, 2002
- Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma ShrinkageThe Journal of Clinical Endocrinology & Metabolism, 1997
- Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergolineThe Journal of Clinical Endocrinology & Metabolism, 1996
- A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic AmenorrheaNew England Journal of Medicine, 1994